Thus, inhibitors of PI3K/AKT/mTOR signaling are promising drug candidates for the treatment of MYB-dependent cancers, which is supported by the outcome of clinical studies with the mTOR inhibitor everolimus for the therapy of advanced ACC, revealing promising activity as monotherapy or in combination with the immune-modulating and antiangiogenic drug lenalidomide[167,168]. Here, PIK3CG is linked to adrenal cortex carcinoma.